Thuja Capital’s Dr. Briejer and Prof. van Brummelen author book chapter
Utrecht, The Netherlands – Dr. Briejer, Investment Director and Partner with Thuja Capital and Prof. Van Brummelen, a seasoned drug development professional who is a member of the Scientific Advisory Board of Thuja have authored a chapter in the recently released new edition of the authoritative pharmaceutical medicine textbook “Drug Benefits and Risks: International Textbook of Clinical Pharmacology”. (more…)
Johnson & Johnson acquires Omrix Biopharmaceuticals
New York, USA – Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops (more…)
Thuja Capital adds Dr. Herbert Heyneker to its Scientific Advisory Board
Utrecht, The Netherlands – Thuja Capital is happy to announce that Herbert Heyneker has accepted to join its Scientific Advisory Board. (more…)
Thuja Capital Healthcare Fund invests in Okapi Sciences
Utrecht, The Netherlands – Thuja Capital has concluded a 8.5 mio Euro financing round in Okapi Sciences. Please find the full press release here.
Avantium Completes EUR 18M financing
Amsterdam, The Netherlands – Avantium has completed a EUR 18M financing. Please find the original press release here.
Omrix Biopharmaceuticals receives EMEA approval for EVICEL
New York, USA – OMRIX Biopharmaceuticals, Inc. (“Omrix” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, (more…)
Epicept receives CEPLENE European marketing approval
New York, USA – Epicept has received marketing authorization from the EMEA for EVICEL. Please be referred to the press release.
Thuja Capital Healthcare Fund invests in Bioceros
Utrecht, The Netherlands – Thuja Capital has closed a seed financial round in Bioceros, a Utrecht, The Netherlands, based biotech company. Please find the press release here.
Curacyte sells subsidiary to The Medicines Company
Munchen, Germany – Curacyte AG today announced that it has sold its wholly owned subsidiary, Curacyte Discovery GmbH based in Leipzig (Germany) to The Medicines Company (NASDAQ: MDCO). Please be referred to the original press release.